Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiffany A Traina

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Breast Cancer Research and Treatment|September 8, 2011
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancerDevika Gajria, Joseph Gonzalez, Kimberly Feigin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
PIK3CA mutation associates with improved outcome in breast cancerKevin Kalinsky, Lindsay M Jacks, Adriana Heguy, et al.
Breast Cancer Research and Treatment|May 11, 2018
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancerAditya Bardia, Ayca Gucalp, Noashir DaCosta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2024
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast CancerTira J Tan, Sarah Sammons, Young-Hyuck Im, et al.
Clinical Breast Cancer|July 7, 2011
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancerAyca Gucalp, Joseph A Sparano, James Caravelli, et al.
Future Oncology (London, England)|August 1, 2023
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancerRebecca A Dent, David W Cescon, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|May 7, 2013
Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysisCarmen A Perez, Zachary S Zumsteg, Gaorav Gupta, et al.
Annals of Surgical Oncology|December 25, 2009
Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancerMatthew S Pugliese, Amer K Karam, Meier Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast CancerLee S Schwartzberg, Denise A Yardley, Anthony D Elias, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 1, 2021
Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlationsDonna C Ferguson, Douglas A Mata, Timothy Ky Tay, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Breast Cancer Research and Treatment|September 8, 2011
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancerDevika Gajria, Joseph Gonzalez, Kimberly Feigin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
PIK3CA mutation associates with improved outcome in breast cancerKevin Kalinsky, Lindsay M Jacks, Adriana Heguy, et al.
Breast Cancer Research and Treatment|May 11, 2018
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancerAditya Bardia, Ayca Gucalp, Noashir DaCosta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2024
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast CancerTira J Tan, Sarah Sammons, Young-Hyuck Im, et al.
Clinical Breast Cancer|July 7, 2011
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancerAyca Gucalp, Joseph A Sparano, James Caravelli, et al.
Future Oncology (London, England)|August 1, 2023
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancerRebecca A Dent, David W Cescon, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|May 7, 2013
Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysisCarmen A Perez, Zachary S Zumsteg, Gaorav Gupta, et al.
Annals of Surgical Oncology|December 25, 2009
Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancerMatthew S Pugliese, Amer K Karam, Meier Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast CancerLee S Schwartzberg, Denise A Yardley, Anthony D Elias, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 1, 2021
Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlationsDonna C Ferguson, Douglas A Mata, Timothy Ky Tay, et al.
Pageof 7